Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2006-12-05
2006-12-05
Channavajjala, Lakshmi (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S434000, C424S449000, C424S464000
Reexamination Certificate
active
07144584
ABSTRACT:
The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
REFERENCES:
patent: 4564706 (1986-01-01), Ecsery et al.
patent: 4812481 (1989-03-01), Reischig et al.
patent: 4861800 (1989-08-01), Buyske
patent: 4925878 (1990-05-01), Bodo et al.
patent: 5075338 (1991-12-01), Knoll et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5225446 (1993-07-01), Milgram
patent: 5234957 (1993-08-01), Mantelle
patent: 5242950 (1993-09-01), Fries Hastings
patent: RE34579 (1994-04-01), Buyske et al.
patent: 5380761 (1995-01-01), Szabó et al.
patent: 0 404 807 (1991-01-01), None
patent: 0 509 761 (1992-10-01), None
patent: 0 593 807 (1994-04-01), None
patent: WO 92/17169 (1992-10-01), None
Roselaar et al. Selegiline in nacrolepsy. Sleep. Oct. 1987, vol. 10(5):491-495.
Hublin. Selegiline in the treatment of nacrolepsy. Neurology 1994 Nov., 44(11):2095-101.
Amenta et al., “Microanatomical Changes in the Frontal Cortex of Aged Rats: Effect of L-Deprenyl Treatment,”Brain Res Bull.34:125-131 (1994).
Ansari et al., “Rescue of Axotomized Immature Rat Facial Motoneurons by R(−)-Deprenyl: Stereospecificity and Independence from Monoamine Oxidase Inhibition,”J. Neurosci.13(9):4042-4053 (1993).
Berry et al., “Possible Mechanisms of Action of (−)Deprenyl and Other MAO-B Inhibitors in Some Neurologic and Psychlatric Disorders,”Prog. in Neurobiol.44:141-161 (1994).
Casper et al., “EGF Enhances the Survival of Dopamine Neurons in Rat Embryonic Mesencephalon Primary Cell Culture,”J. Neurosci. Res.30:372-381 (1991).
Glover et al., “Neurotoxins and Monoamine Oxidase B Inhibitors: Possible Mechanisms for the Neuroprotective Effect of (−)-Deprenyl,”Inhibitors of Monoamine Oxidase B,Chapter 8 (1993).
Iwasaki et al., “Deprenyl Enhances Neurite Outgrowth in Cultured Rat Spinal Ventral Horn Neurons,”J. Neurol Sci.125:11-13 (1994).
Ju et al., “(−)-Deprenyl Alters the Time Course of Death of Axotomized Facial Motoneurons and the Hypertrophy of Neighoring Astrocytes In Immature Rats,”Exp. Neurol.126:233-246 (1994).
Matsui et al., Monoamine Oxidase Inhibitors Prevent Striatal Neuronal Necrosis Induced by Transient Forebrain Ischemia,Neurosci.Lett.126:175-178 (1991).
Park et al., “Protection from 1-Methyl-4-Phenylpyridinium (MPP+) Toxicity and Stimulation of Regrowth of MPP+-damage Dopaminergic Fibers by Treatment of Mesencephalic Cultures with EGF and Basic FGF,”Basic Res.599:83-97 (1992).
Rinne, “Nigral Degeneration in Parkinson's Disease in Relation to Clinical Features,”Acta Neurol. Scand. 84(supp. 136): 87-90 (1991).
Rinne et al., “Selegiline (Deprenyl) Treatment and Death of Nigral Neurons in Parkinson's Disease,”Neurology41:859-861 (1991).
Salo et al., “Deprenyl Reduces the Death of Motoneurons Caused by Axotomy,”J. Neurosci. Res.31:394-400 (1992).
Tatton, “Selegiline Can Mediate Neuronal Rescue Rather Than Neuronal Protection,”Movement Disorders8:520-530 (1993).
Tatton et al., “‘Trophic-Like’ Actions of (−)-Deprenyl on Neurons and Astroglia,” inRecent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction7:238-248 (1994).
Zeng et al., “Influence of Long-Term Treatment with L-Deprenyl on the Age-Dependent Changes in Rat Brain Microanatomy,”Mech. Ageing Dev.73:113-126 (1994).
Borbe et al., “Kinetic Evaluation of MAO-B-Activity Following Oral Administration of Selegiline and Desmethyl-Selegiline in the Rat,”J. Neural. Transm.32:131-137 (19990).
Gershon et al., “Monoamine Oxidase Inhibition and the Induction of Ponto-Geniculo-Occipital Wave Activity by Reserpine in the Cat,”J. Pharmacol. Exp. Ther.197:556-566 (1976).
Helnonen et al., “Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects,”Neurology43:A156 (1993).
Heinonen et al., “Pharmacokinetic Aspects of l-Deprenyl (Selegiline) and Its Metabolites,”Clin. Pharmacol. Ther.56:742-749 (1994).
Heinonen et al., “Pharmacokinetics and Metabolism of Selegiline,”Acta. Neurol. Scand.126:93-99 (1989).
Martin et al., “Regression Analysis of the Relationship between Physical Properties and the in Vitro Inhibition of Monoamine Oxidase by Propynylamines,”J. Med. Chem.18:883-888 (1975).
Nickel et al., “Effect of Selegiline and Desmethyl-Selegiline on Cortical Electric Activity in Rats,”J. Neural. Transm. 32:139-144 (1990).
Williams et al., “Biochemical and Behavioural Studies of Monoamine Oxidase Inhibition,”Ir. J. Med. Sci. 147:71-74 (1978).
Channavajjala Lakshmi
Somerset Pharmaceuticals, Inc.
Vinson & Elkins LLP
LandOfFree
S(+) desmethylselegiline and its use to treat narcolepsy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S(+) desmethylselegiline and its use to treat narcolepsy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S(+) desmethylselegiline and its use to treat narcolepsy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708255